Two Proteins Target Astrocytes and Aβ42 to Slow Alzheimer’s Progression

Astrocytes and Aβ42: New Targets in Alzheimer’s Research

Scientists have uncovered two new ways to slow Alzheimer’s by targeting specific proteins. Researchers at Baylor College of Medicine showed that boosting Sox9 levels revives aging astrocytes, letting them clear amyloid-beta plaques. Meanwhile, a team at the University of Cincinnati found that higher Aβ42 levels linked to slower cognitive decline. These results point to several possible treatments for neurodegenerative diseases.

Astrocytes, star-shaped glial cells, support neurons and manage the blood-brain barrier. The Baylor team found that aging weakens astrocyte function, making it harder to clear amyloid plaques. By tweaking Sox9 levels, they saw better memory and behavior in mice with Alzheimer’s symptoms. This matches earlier work showing microglia can clear beta-amyloid, though past attempts had technical limits. The study highlights Sox9’s activation of the MEGF10 receptor as a key process, improving astrocyte phagocytosis of plaques.

While these results are promising, challenges remain. The Baylor study, done on mice, needs human trials to confirm. Long-term effects of Sox9 overexpression on astrocytes and possible side effects are unknown. Similarly, the University of Cincinnati study, based on 26,000 patients, requires more validation. Dr. Benjamin Deneen said, ‘Most treatments focus on neurons or stop plaque formation. This study suggests boosting astrocytes’ natural cleanup ability could be just as important,’ but human use hasn’t been tested. Some researchers argue that Aβ42‘s protective role might depend on context, and higher levels could worsen plaques in certain cases.

These studies fit into a growing trend re-evaluating glial cells in disease. In the 1990s, studies showed microglia could clear beta-amyloid, but technical hurdles slowed progress. The Baylor study identifies Sox9 as a key regulator, offering a targeted approach. The University of Cincinnati findings challenge traditional views of Alzheimer’s, suggesting insufficient Aβ42 levels, not plaque buildup, might drive cognitive decline. These studies reflect a broader shift toward understanding glial cell roles in neurodegenerative diseases. A 2021 Nature Neuroscience review linked astrocyte dysfunction to Parkinson’s and ALS, highlighting potential for glial-targeted therapies.

The Baylor study measured plaque reduction and cognitive function in mice with Alzheimer’s symptoms. Mice with higher Sox9 levels kept memory function stable over six months compared to controls. Dr. Dong-Joo Choi said, ‘Activating astrocytes to clear plaques can help slow mental decline,’ supported by better object recognition tests. The University of Cincinnati study found higher Aβ42 levels after treatment linked to slower cognitive decline in 26,000 patients, suggesting boosting Aβ42 might be a treatment option. However, the study’s reliance on observational data rather than controlled trials raises questions about causality. Dr. Sarah J. H. L. van der Vegt noted, ‘We need to tell the difference between correlation and causation—Aβ42 might be a biomarker rather than a direct target.’

These findings fit into a broader trend exploring astrocyte-based interventions. Recent studies connect astrocyte dysfunction to other neurodegenerative diseases like Parkinson’s and ALS. The Baylor study may pave the way for therapies targeting glial cells across multiple conditions. With Alzheimer’s patients expected to reach 1.5 billion by 2050, such innovations could have major impacts. The University of Cincinnati research challenges the amyloid hypothesis, suggesting Alzheimer’s might be caused by low Aβ42 levels rather than plaque accumulation, potentially changing treatment strategies.

Translating these findings to human therapies requires overcoming several hurdles. Researchers must figure out optimal protein levels, possible side effects, and delivery methods. Funding from the National Institutes of Health and private foundations, including the David and Eula Wintermann Foundation, will be key. Dr. Deneen said, ‘The findings open the door to new therapies that aim to use astrocytes as a natural defense against neurodegenerative disease,’ but the path from mice to humans is complex. Similarly, the University of Cincinnati findings highlight the need for more clinical trials to validate Aβ42‘s role in cognitive preservation. For example, a phase II trial of lecanemab, which accidentally boosts Aβ42 levels, showed a 27% reduction in cognitive decline, but long-term safety data remains limited.

The discovery of Sox9‘s role in astrocyte function and the identification of Aβ42‘s protective role mark a shift in Alzheimer’s research. By focusing on the brain’s natural cleanup systems, scientists may unlock new treatments. While challenges remain, these studies emphasize the importance of re-evaluating traditional targets and embracing the complexity of the brain’s support systems. As research continues, these findings could lead to breakthroughs for Alzheimer’s and other neurodegenerative diseases, changing how we approach neurodegeneration in the 21st century.